Clinical Trial: GKL-006Allo Injection in Patients With Advanced Solid Tumors

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07704515) titled 'GKL-006Allo Injection in Patients With Advanced Solid Tumors' on July 09.

Brief Summary: This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.

Study Start Date: Aug. 30

Study Type: INTERVENTIONAL

Condition: Solid Tumor Malignancies

Intervention: BIOLOGICAL: GKL-006Allo Injection

GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy. It will be administered according to the dose level, dosing schedule, and treatment stage specified i...